MDxHealth (NASDAQ:MDXH) Stock Price Expected to Rise, TD Cowen Analyst Says

MDxHealth (NASDAQ:MDXH) had its price target increased by equities researchers at TD Cowen from $5.00 to $7.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s target price would indicate a potential upside of 92.31% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Craig Hallum started coverage on shares of MDxHealth in a research note on Thursday, July 17th. They set a “buy” rating and a $8.00 price target on the stock. BTIG Research boosted their price objective on shares of MDxHealth from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Lake Street Capital raised their target price on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Stock Performance

MDXH stock opened at $3.64 on Thursday. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. MDxHealth has a 1 year low of $1.35 and a 1 year high of $5.33. The company has a market cap of $172.13 million, a P/E ratio of -4.14 and a beta of 1.68. The stock’s fifty day moving average price is $4.32 and its 200-day moving average price is $3.06.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The firm had revenue of $27.43 million during the quarter, compared to the consensus estimate of $24.11 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its FY 2025 guidance at EPS. On average, equities analysts forecast that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new stake in MDxHealth in the 3rd quarter worth $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth in the third quarter worth about $53,000. Calamos Advisors LLC bought a new position in shares of MDxHealth in the third quarter worth about $305,000. Russell Investments Group Ltd. purchased a new stake in shares of MDxHealth during the third quarter worth about $461,000. Finally, FreeGulliver LLC bought a new stake in MDxHealth during the 2nd quarter valued at approximately $273,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.